We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria.
- Authors
Baumann, Katrine; Jørgensen, Astrid‐Helene Ravn; Sørensen, Jennifer Astrup; Zhang, Ditte Georgina; Ghazanfar, Misbah Noshela; Skov, Per Stahl; Woetmann, Anders; Vestergaard, Christian; Maurer, Marcus; Thomsen, Simon Francis
- Abstract
A study published in the journal Clinical & Experimental Allergy found that a positive basophil histamine release assay (BHRA) can help identify patients with type IIb chronic spontaneous urticaria (CSU) who are less likely to respond to standard-dosed omalizumab treatment. CSU patients with type IIb autoimmunity have a higher disease severity and are more refractory to antihistamines and omalizumab. The study also found that BHRA positivity occurs in approximately one out of seven CSU patients and may be used as a predictor of a poorer response to omalizumab, indicating the need for off-label use in these patients.
- Subjects
OMALIZUMAB; HISTAMINE; BASOPHILS; URTICARIA; OFF-label use (Drugs)
- Publication
Clinical & Experimental Allergy, 2023, Vol 53, Issue 12, p1318
- ISSN
0954-7894
- Publication type
Article
- DOI
10.1111/cea.14402